Dolph Ellefson

Dolph Ellefson has a diverse and extensive work experience. Starting in 1993, they pursued their doctoral studies at Loyola University Chicago until 1996. In 1997, they joined Oregon Health & Science University as a Post-Doctoral Fellow and Research Assistant Professor, conducting studies on microbial pathogenesis and teaching medical students. During this time, they also received a patent for a novel mechanism related to the study of pathogenic bacteria.

Dolph then moved to the University of Southern California in 2002, where they served as an Assistant Professor and contributed to research studies on a biological drug for wound healing. Dolph played a role in securing significant funding for radiation research through grants. In 2008, they transitioned to the position of Associate Director at USC's Small Molecule Mass Spectrometry CORE.

In 2009, Ellefson joined Neumedicines, a small pharmaceutical company, as a Senior Scientist in Pharmaceutical R&D. Dolph'swork focused on leading scientific studies and supervising a team for the development of a biologic drug aimed at treating radiation exposure. Dolph also discovered the drug's robust wound healing properties and submitted a patent application.

In 2014, they founded Sarcix, Inc. and served as both Founder and COO. The company's focus and activities are not mentioned.

Most recently, in 2021, Ellefson joined mapEDU as the COO. This cloud-based, AI software company specializes in curriculum mapping for higher education. Notably, in March 2022, they were promoted to the position of Director of Research and Innovation.

Dolph Ellefson attended the Stritch School of Medicine from 1990 to 2008, where they completed their PhD in Microbiology/Immunology.